natgillin/translations-raw huggingface dataset:
Infektioner og parasitære sygdomme Ikke almindelig:
Infections and infestations Uncommon:
Thiazider kan øge risikoen for bivirkninger ved behandling med amantadin.
Thiazides may increase the risk of adverse effects caused by amantadine.
Hvis Kinzalkomb tages mere end 3 måneder henne i graviditeten, kan det forårsage alvorlige fosterskader (se afsnit Graviditet).
Kinzalkomb is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 brugere): Utilpashed (kvalme), lavt magnesiumindhold i blodet.
Common side effects (may affect up to 1 in 10 people): Feeling sick (nausea), low blood magnesium level.
Psykiske forstyrrelser Ikke kendt:
Psychiatric disorders Not known:
Hypokaliæmi Hyperurikæmi, hyponatræmi
Hypokalaemia Hyperuricaemia, hyponatraemia
LÆGEMIDLETS NAVN Kinzalkomb 80 mg/25 mg tabletter
NAME OF THE MEDICINAL PRODUCT Kinzalkomb 80 mg/25 mg tablets
Yderligere oplysninger om de enkelte komponenter Tidligere rapporterede bivirkninger for de enkelte indholdsstoffer kan også være potentielle bivirkninger i forbindelse med Kinzalkomb, selvom de ikke er observeret i kliniske forsøg med dette produkt.
Adverse reactions previously reported with one of the individual components may be potential adverse reactions with Kinzalkomb, even if not observed in clinical trials with this product.
Sådan skal du tage Kinzalkomb
How to take Kinzalkomb
ANVENDELSESMÅDE OG ADMINISTRATIONSVEJ(E) Læs indlægssedlen inden brug.
METHOD AND ROUTE(S) OF ADMINISTRATION Oral use
Der er intet, der tyder på, at Kinzalkomb kan reducere eller forhindre diuretika forårsaget hyponatriæmi.
- Hyponatraemia and hypochloraemic alkalosis There is no evidence that Kinzalkomb would reduce or prevent diuretic-induced hyponatraemia.
Erfaringer med andre lægemidler, som hæmmer reninangiotensinsystemet viser, at samtidig brug af ovennævnte produkter kan føre til stigning i serumkalium.
Based on the experience with the use of other medicinal products that blunt the renin-angiotensin system, concomitant use of the above medicinal products may lead to increases in serum potassium and is, therefore, not recommended (see section
Én 80 mg/12,5 mg tablet indeholder 112 mg lactosemonohydrat og 338 mg sorbitol (E420).
Each 80 mg/12.5 mg tablet contains 112 mg of lactose monohydrate and 338 mg sorbitol (E420).
Øvre luftvejsinfektion (f.eks. ondt i halsen, bihulebetændelse, almindelig forkølelse), urinvejsinfektion, blodmangel (anæmi), høje kaliumniveauer, langsom hjerterytme (bradykardi), nedsat nyrefunktion inklusive akut nyresvigt, svaghed, hoste.
Upper respiratory tract infection (e.g. sore throat, inflamed sinuses, common cold), urinary tract infections, deficiency in red blood cells (anaemia), high potassium levels, slow heart rate (bradycardia), kidney impairment including acute kidney failure, weakness, cough.
INFORMATION I BRAILLESKRIFT Kinzalkomb 80 mg/25 mg
INFORMATION IN BRAILLE Kinzalkomb 80 mg/25 mg
• Hjerteproblemer
- Heart trouble.
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 brugere): Svimmelhed.
Common side effects (may affect up to 1 in 10 people): Dizziness
- Blodtrykssænkende medicin, binyrebarkhormoner (kortikosteroider), smertestillende medicin såsom non-steroide antiinflamatoriske lægemider (NSAID), medicin til behandling af cancer, urinsyregigt (podagra) eller leddegigt.
Other medicines used to treat high blood pressure, corticosteroids, painkillers (such as nonsteroidal anti-inflammatory drugs [NSAIDs]), medicines to treat cancer, gout, or arthritis.
Ikke almindelig: Sjælden:
Uncommon: Rare:
• Forsnævring af blodkarrene til den ene eller begge nyrer (nyre-arteriestenose)
- Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).
Hos patienter, der kun får hydrochlorthiazid, er der, i tillæg til de bivirkninger, som er nævnt for Kinzalkomb, set følgende bivirkninger:
Hydrochlorothiazide In patients taking hydrochlorothiazide alone the following additional side effects have been reported:
• hvis du er allergisk over for telmisartan eller et af de øvrige indholdsstoffer i Kinzalkomb
• if you are allergic to telmisartan or any other ingredients of this medicine (listed in section 6).
EU/1/02/214/011 14 tabletter EU/1/02/214/012 28 tabletter EU/1/02/214/013 28 x 1 tabletter EU/1/02/214/014 56 tabletter EU/1/02/214/015 98 tabletter
EU/1/02/214/011 14 tablets EU/1/02/214/012 28 tablets EU/1/02/214/013 28 x 1 tablets EU/1/02/214/014 56 tablets EU/1/02/214/015 98 tablets
INFORMATION I BRAILLESKRIFT Kinzalkomb 40 mg/12,5 mg
INFORMATION IN BRAILLE Kinzalkomb 40 mg/12.5 mg
Rød jernoxid (E172) Natriumhydroxid Natriumstivelsesglycolat (type A) Sorbitol (E420)
Red ferric oxide (E172) Sodium hydroxide Sodium starch glycollate (type A) Sorbitol (E420).
I prækliniske studier blev der ikke påvist nedsat fertilitet hos hunner eller hanner ved brug af telmisartan.
In preclinical studies, no effects of telmisartan and hydrochlorothiazide on male and female fertility were observed.
• hvis du har alvorlige leverproblemer, som f.eks. galdeophobning i galdegangene eller problemer med udskillelse af galde fra leveren og galdeblæren
• if you have severe liver problems such as cholestasis or biliary obstruction (problems with drainage of the bile from the liver and gall bladder) or any other severe liver disease.
Svaghed
Weakness
• Kinzalkomb 80 mg/12,5 mg én gang dagligt er til patienter, hvis blodtryk ikke kan reguleres tilfredsstillende med Kinzalmono 80 mg.
• Kinzalkomb 80 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Kinzalmono 80 mg
Kinzalkomb bør ikke gives til patienter med kolestase, biliære obstruktive sygdomme eller svær leverinsufficiens (se pkt.
Kinzalkomb should not be given to patients with cholestasis, biliary obstructive disorders or severe hepatic insufficiency (see section 4.3) since telmisartan is mostly eliminated with the bile.
Advarselstegn på væske- eller elektrolytforstyrrelser er mundtørhed, tørst, asteni, sløvhed, døsighed, uro, muskelsmerter eller kramper, muskeltræthed, hypotension, oliguri, takykardi og gastrointestinale problemer i form af kvalme eller opkastning (se pkt.
Warning signs of fluid or electrolyte imbalance are dryness of mouth, thirst, asthenia, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting (see section 4.8).
Forhøjet serumkreatinin, forhøjet kreatininkinase i blodet, forhøjede leverenzymer
Blood creatinine increased, blood creatine phosphokinase increased, hepatic enzyme increased
Synsforstyrrelser, sløret syn
Visual disturbance, vision blurred
Hvis det ikke behandles, kan det føre til permanent synstab.
This can lead to permanent vision impairment, if not treated.
Hoste Interstitiel lungesygdom
Cough Interstitial lung disease
Nedenstående bivirkninger, der er blevet rapporteret for de to aktive indholdsstoffer, er også mulige bivirkninger for Kinzalkomb, selvom de ikke er set i kliniske studier med dette lægemiddel.
Adverse reactions reported with one of the individual components may be potential adverse reactions with Kinzalkomb, even if not observed in clinical trials with this product.
Dette lægemiddel indeholder lactosemonohydrat og sorbitol og bør ikke anvendes til patienter med arvelig fructoseintolerans, arvelig galactoseintolerans, en særlig form for arvelig lactasemangel (Lapp Lactase deficiency) eller glucose/galactosemalabsorption.
Patients with rare hereditary problems of fructose intolerance and/or with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
Gul jernoxid (E172) Natriumhydroxid Natriumstivelsesglycolat (type A) Sorbitol (E420)
Yellow ferric oxide (E172) Sodium hydroxide Sodium starch glycollate (type A) Sorbitol (E420).
Tilgængelige data fra epidemiologiske studier viser en kumulativ dosis-afhængig forbindelse mellem hydrochlorthiazid og non-melanom hudkræft.
Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed.
Kinzalkomb bruges til at sænke forhøjet blodtryk (essentiel hypertension) hos voksne, hvis blodtryk ikke kan reguleres tilfredsstillende med Kinzalkomb 80 mg/12,5 mg eller til patienter, som tidligere er stabiliseret på telmisartan og hydrochlorothiazid givet hver for sig.
Kinzalkomb is used to treat high blood pressure (essential hypertension) in adults whose blood pressure is not adequately controlled by Kinzalkomb 80/12.5 mg or in patients who have been previously stabilised by telmisartan and hydrochlorothiazide given separately.
EU/1/02/214/006 14 tabletter EU/1/02/214/007 28 tabletter EU/1/02/214/008 28 x 1 tabletter EU/1/02/214/009 56 tabletter EU/1/02/214/010 98 tabletter
EU/1/02/214/006 14 tablets EU/1/02/214/007 28 tablets EU/1/02/214/008 28 x 1 tablets EU/1/02/214/009 56 tablets EU/1/02/214/010 98 tablets
Blodtrykssænkningen med Kinzalkomb kan blive mindre ved samtidig brug af medicin mod gigt og lette smerter (non-steroid antiinflammatorisk medicin (NSAID)), f.eks. acetylsalicylsyre eller ibuprofen.
The effect of Kinzalkomb may be reduced when you take NSAIDs (non-steroidal anti-inflammatory medicines, e.g. aspirin or ibuprofen).
Kinzalkomb er pakket i blisterpakninger med 14, 28, 56 eller 98 tabletter eller enkelt dosis blister pakninger indeholdende 28 x 1 tabletter.
Kinzalkomb is available in blisters packs containing 14, 28, 56, or 98 tablets, or unit dose blister packs containing 28 x 1 tablets.
Hvis angiotensin IIreceptorantagonister har været anvendt fra andet trimester, bør nyrefunktionen og kraniet kontrolleres ved hjælp af ultralyd.
Should exposure to angiotensin II receptor antagonists have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.
EU/1/02/214/001 14 tabletter EU/1/02/214/002 28 tabletter EU/1/02/214/003 28 x 1 tabletter EU/1/02/214/004 56 tabletter EU/1/02/214/005 98 tabletter
EU/1/02/214/001 14 tablets EU/1/02/214/002 28 tablets EU/1/02/214/003 28 x 1 tablets EU/1/02/214/004 56 tablets EU/1/02/214/005 98 tablets
Almene symptomer og reaktioner på administrationsstedet Ikke almindelig: Sjælden:
Erectile dysfunction General disorders and administration site conditions Uncommon: Rare:
Blod og lymfesystem Sjælden:
Blood and lymphatic system disorders Uncommon:
Sepsis* (ofte kaldet "blodforgiftning") er en alvorlig infektion med betændelsesreaktion i hele kroppen, hurtig hævelse af hud og slimhinder (angioødem), blærer og afskalning af det øverste lag af huden (toksisk epidermal nekrolyse).
Sepsis* (often called "blood poisoning", is a severe infection with whole-body inflammatory response), rapid swelling of the skin and mucosa (angioedema), blistering and peeling of the top layer of skin (toxic epidermal necrolysis); these side effects are rare (may affect up to 1 in 1,000 people) or of unknown frequency (toxic epidermal necrolysis) but are extremely serious and patients should stop taking the medicine and see their doctor immediately.
Telmisartan fjernes ikke ved hæmodialyse.
Telmisartan is not removed by haemodialysis.
Pakningsstørrelse: - Blister med 14, 28, 56 eller 98 tabletter eller - Perforeret enkeltdosis blister med 28 x 1 tabletter.
Pack sizes: - Blister with 14, 28, 56, or 98 tablets or - Perforated unit dose blisters with 28 x 1 tablets.
I fastdosiskombinationen er Kinzalkomb (80 mg telmisartan/25 mg hydrochlorthiazid) indiceret til voksne, hvis blodtryk ikke kan reguleres tilfredsstillende med Kinzalkomb 80 mg/12,5 mg (80 mg telmisartan/12,5 mg hydrochlorothiazid) eller til patienter, som tidligere er stabiliseret på telmisartan og hydrochlorothiazid givet hver for sig.
Kinzalkomb fixed dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Kinzalkomb 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
KVALITATIV OG KVANTITATIV SAMMENSÆTNING Én tablet indeholder 80 mg telmisartan og 25 mg hydrochlorthiazid.
QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 80 mg telmisartan and 25 mg hydrochlorothiazide.
INFORMATION I BRAILLESKRIFT Kinzalkomb 80 mg/12,5 mg
INFORMATION IN BRAILLE Kinzalkomb 80 mg/12.5 mg
• Kinzalkomb 80 mg/25 mg én gang daglig kan gives til patienter, hvis blodtryk ikke kan reguleres tilfredsstillende med Kinzalkomb 80 mg/12,5 mg eller til patienter, som tidligere er stabiliseret på telmisartan og hydrochlorothiazid givet hver for sig.
Kinzalkomb 80 mg/25 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Kinzalkomb 80 mg/12.5 mg or in patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Hypokaliæmi kan ved samtidig brug af digitalisglykosider eller visse antiarytmika resultere i muskelkramper og/eller accentueret arytmi.
Hypokalaemia may result in muscle spasms and/or accentuate arrhythmia associated with the concomitant use of digitalis glycosides or certain antiarrhythmic medicinal products.
- visse antipsykotika (fx thioridazin, chlorpromazin, levomepromazin, trifluoperazin, cyamemazin, sulpirid, sultoprid, amisulprid, tiaprid, pimozid, haloperidol, droperidol) - andre (fx bepridil, cisaprid, diphemanil, erythromycin i.v., halofantrin, mizolastin, pentamidin, sparfloxacin, terfenadin, vincamin i.v.)
cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol) - others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin,
Øvrige indholdsstoffer: Lactosemonohydrat, magnesiumstearat, majsstivelse, meglumin, mikrokrystallinsk cellulose, povidon, rød jernoxid (E172), natriumhydroxid, natriumstivelseglykollat (type A) og sorbitol (E420).
The other ingredients are lactose monohydrate, magnesium stearate, maize starch, meglumine, microcrystalline cellulose, povidone, red iron oxide (E172), sodium hydroxide, sodium starch glycollate (type A), sorbitol (E420).
Øvrige indholdsstoffer: Lactosemonohydrat, magnesiumstearat, majsstivelse, meglumin, mikrokrystallinsk cellulose, povidon, gul jernoxid (E172), natriumhydroxid, natriumstivelseglykollat (type A), sorbitol (E420).
The other ingredients are lactose monohydrate, magnesium stearate, maize starch, meglumine, microcrystalline cellulose, povidone, yellow iron oxide (E172), sodium hydroxide, sodium starch glycollate (type A), sorbitol (E420).
Kinzalkomb må ikke gives til patienter med svært nedsat leverfunktion.
Kinzalkomb is not indicated in patients with severe hepatic impairment.
Kinzalkomb 80 mg/25 mg tabletten er gul og hvid, oval og er i 2 lag hvorpå koden ”H9” er præget.
Kinzalkomb 80 mg/25 mg tablets are yellow and white, oval-shaped, two-layer tablets engraved with the code 'H9'.
Det kan være andre vanddrivende tabletter (diuretika), afføringsmidler (f.eks. amerikansk olie), kortikosteroider (f.eks. prednison), ACTH (et hormon), amphotericin (mod svampeinfektion), carbenoxolen (til at behandle mundsår), benzylpenicillin (et antibiotikum) og salicylsyre og hermed beslægtede stoffer.
Medicines associated with low blood potassium (hypokalaemia) such as other diuretics, ('water tablets'), laxatives (e.g. castor oil), corticosteroids (e.g. prednisone), ACTH (a hormone), amphotericin (an antifungal medicine), carbenoxolone (used to treat mouth ulcers), penicillin G sodium (an antibiotic), and salicylic acid and derivatives.
Betændelse i en spytkirtel, hud- og læbekræft (non-melanom hudkræft), lavt (eller endda manglende) indhold af røde og hvide blodlegemer, alvorlig allergisk reaktion (f.eks. overfølsomhed, anafylaktisk reaktion), appetitløshed, rastløshed, svimmelhed, sløret eller gulligt syn, synsnedsættelse og øjensmerter (mulige tegn på akut nærsynethed eller akut snævervinklet glaukom), betændelse i blodkarrene (nekrotiserende vaskulit), betændt bugspytkirtel, maveproblemer, gul i huden eller øjnene (gulsot), lupus-lignende symptomer (bivirkninger som ligner en sygdom kaldet systemisk lupus erythematosus, hvor kroppens immunsystem angriber kroppen), hudsygdomme som f.eks. betændte blodkar i huden, øget følsomhed for sollys, udslæt, hudrødme, blærer på læber, øjne eller mund, afskalning af hud, feber (mulige tegn på erythema multiforme), svaghed, nyrebetændelse eller nedsat nyrefunktion, sukker i urinen (glykosuri), feber, forstyrrelse i elektrolytbalancen, højt indhold af kolesterol i blodet, nedsat blodvolumen, forhøjet sukkerindhold i blodet, usikkerhed med at kontrollere sukkerindholdet i blod/urin hos patienter med diabetes mellitus eller forhøjet fedtindhold i blodet.
Inflammation of the salivary gland, skin and lip cancer (non-melanoma skin cancer), decreases in the number (or even lack) of cells in the blood, including low red and white blood cell count, , serious allergic reactions (e.g. hypersensitivity, anaphylactic reaction), decreased or loss of appetite, restlessness, light-headedness, blurred or yellowing of vision, decrease in vision and eye pain (possible signs of acute myopia or acute-angle closure glaucoma), inflammation of blood vessels (vasculitis necrotising), inflamed pancreas, upset stomach, yellowing of the skin or eyes (jaundice), lupus-like syndrome (a condition mimicking a disease called systemic lupus erythematosus where the body's immune system attacks the body); skin disorders such as inflamed blood vessels in the skin, increased sensitivity to sunlight, rash, redness of the skin, blistering of the lips, eyes or mouth, skin peeling, fever (possible signs of erythema multiforme), weakness, kidney inflammation or impaired kidney function, glucose in the urine (glycosuria), fever, impaired electrolyte balance, high blood cholesterol levels, decreased blood volume, increased blood levels of glucose, difficulties in controlling blood/ urine levels of glucose in patients with a diagnosis of diabetes mellitus, or fat in the blood.
Omvendt kan hyperkaliæmi optræde på grund af telmisartans antagonistiske effekt på angiotensin II (AT1)-receptorerne.
Conversely, due to the antagonism of the angiotensin II (AT1) receptors by the telmisartan component of Kinzalkomb, hyperkalaemia might occur.
Nekrotiserende vaskulit
Vasculitis necrotizing
- klasse 1a-antiarytmika, (fx quinidin, hydroquinidin, disopyramid) - klasse 3-antiarytmika, (fx amiodaron, sotalol, doftilid, ibutilid)
- class Ia antiarrythmics (e.g. quinidine, hydroquinidine, disopyramide) - class III antiarrythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide) - some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine,
Hypercalcæmi
Hypercalcaemia
Der er dog kun rapporteret om minimal eller ingen påvirkning ved den mængde thiazid (12,5 mg), som findes i Kinzalkomb.
An increase in cholesterol and triglyceride levels has been associated with thiazide diuretic therapy; however, at the 12.5 mg dose contained in Kinzalkomb, minimal or no effects were reported.
Vaskulære sygdomme Ikke kendt:
Vascular disorders Not known:
Nedsat kaliumindhold i blodet, angst, besvimelse, snurrende, prikkende og stikkende fornemmelse (paræstesi), følelse af at dreje rundt (svimmelhed), hjertebanken (takykardi), forstyrret hjerterytme, lavt blodtryk, et pludseligt fald i blodtrykket når du rejser dig op, stakåndethed (dyspnø), diarré, mundtørhed, luftafgang fra tarmen, rygsmerter, muskeltrækninger, muskelsmerter, erektil dysfunktion (manglende evne til at få eller opretholde erektion), brystsmerter, forhøjet urinsyreindhold i blodet.
Decreased blood potassium levels, anxiety, fainting (syncope), sensation of tingling, pins and needles (paraesthesia), feeling of spinning (vertigo), fast heart beat (tachycardia), heart rhythm disorders, low blood pressure, a sudden fall in blood pressure when you stand up, shortness of breath (dyspnoea), diarrhoea, dry mouth, flatulence, back pain, muscle spasm, muscle pain, erectile dysfunction (inability to get or keep an erection), chest pain, increased blood uric acid levels.
Pakningsstørrelse: - Blister med 14, 28, 56, eller 98 tabletter eller - Perforeret enkeltdosis blister med 28 x 1 tabletter.
Pack sizes: -Blister with 14, 28, 56, or 98 tablets or -Perforated unit dose blisters with 28 x 1 tablets
Du skal derfor tale med din læge om eventuelt at få ændret doseringen af din medicin.
You should consult with your doctor if you need to adjust the dose of your other medicine while taking Kinzalkomb.
Lungebetændelse (bronkitis), provokation eller forværring af systemisk lupus erythematosus (en sygdom, hvor kroppens immunsystem angriber kroppen, hvilket forårsager ledsmerter, hududslæt og feber); ondt i halsen, bihulebetændelse, tristhed (depression), besvær med at falde i søvn (insomni), forringet syn, besvær med at trække vejret, mavesmerter, forstoppelse, oppustethed (dyspepsi), utilpashed (opkastning), mavekatar, unormal leverfunktion (japanske patienter har større sandsynlighed for at få denne bivirkning), rødme af huden, allergiske reaktioner såsom kløe eller udslæt, øget svedproduktion, nældefeber (urticaria), ledsmerter (artralgi) og smerter i arme og ben, muskelkramper, influenzalignende symptomer, smerter.
Inflammation of the lung (bronchitis), activation or worsening of systemic lupus erythematosus (a disease where the body's immune system attacks the body, which causes joint pain, skin rashes and fever); sore throat, inflamed sinuses, feeling sad (depression), difficulty falling asleep (insomnia), impaired vision, difficulty breathing, abdominal pain, constipation, bloating (dyspepsia), feeling sick (vomiting), inflammation of the stomach (gastritis), abnormal liver function (Japanese patients are more likely to experience this side effect); redness of the skin (erythema), allergic reactions such as itching or rash, increased sweating, hives (urticaria), joint pain (arthralgia) and pain in extremities, muscle cramps, flu-like-illness, pain, low levels of sodium, increased levels of creatinine, hepatic enzymes or creatine phosphokinase in the blood.
Det anbefales at stoppe behandlingen, hvis en lysoverfølsomhedsreaktion forekommer.
If a photosensitivity reaction occurs during treatment, it is recommended to stop the treatment.
Kinzalkomb findes i styrkerne 40 mg/12,5 mg og 80 mg/12,5 mg.
Kinzalkomb is also available at the dose strengths 40 mg/12.5 mg and 80 mg/12.5 mg Renal impairment
Kinzalkomb 40 mg/12,5 mg tabletter Én tablet indeholder 40 mg telmisartan og 12,5 mg hydrochlorthiazid.
Kinzalkomb 40 mg/12.5 mg tablets Each tablet contains 40 mg telmisartan and 12.5 mg hydrochlorothiazide.
Tilgængelige data fra epidemiologiske studier viser en kumulativ dosis-afhængig forbindelse mellem hydrochlorthiazid og non-melanom hudkræft (se også pkt.
Based on available data from epidemiological studies, cumulative dose-dependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).
Kinzalkomb 80 mg/12,5 mg tabletter Én tablet indeholder 80 mg telmisartan og 12,5 mg hydrochlorthiazid.
Kinzalkomb 80 mg/12.5 mg tablets Each tablet contains 80 mg telmisartan and 12.5 mg hydrochlorothiazide.
Hjælpestoffer, som behandleren skal være opmærksom på Én tablet indeholder 99 mg lactosemonohydrat og 338 mg sorbitol (E420).
Each tablet contains 99 mg of lactose monohydrate and 338 mg sorbitol (E420).
Luftveje, thorax og mediastinum Ikke almindelig:
Hypotension, orthostatic hypotension Respiratory, thoracic and mediastinal disorders Uncommon: Rare:
- Medicin, der kan forhøje indholdet af kalium i blodet, såsom vanddrivende medicin, kaliumtilskud, saltsubstitutter som indeholder kalium og ACE-hæmmere (blodtrykssænkende medicin), ciclosporin (undertrykker kroppens immunforsvar) og andre lægemidler såsom heparinnatrium (blodfortyndende medicin) .
Medicines that may increase blood potassium levels such as potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, ACE inhibitors, cyclosporin (an immunosuppressant drug) and other medicinal products such as heparin sodium (an anticoagulant).